Dr Charles Jaffe, MD, PHD in Del Mar, CA - Allergy & Immunology

Dr Charles Jaffe, MD, PHD is a Allergy & Immunology physician based in Del Mar, California. Dr Charles Jaffe is licensed to practice in California (license number C37310) and his current practice location is 1619 Forest Way, Del Mar, California. He can be reached at his office (for appointments etc.) via phone at (858) 720-8200.

NPI number for Dr Charles Jaffe is 1114259827 and his current mailing address is 1619 Forest Way, Del Mar, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1114259827.

Contact Information

	Dr Charles Jaffe, MD, PHD
	1619 Forest Way, Del Mar, CA 92014-2430
	(858) 720-8200
	Not Available

Physician's Profile

Full Name	Dr Charles Jaffe
Gender	Male
Speciality	Allergy & Immunology
Location	1619 Forest Way, Del Mar, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1114259827
Provider Enumeration Date: 02/04/2010
Last Update Date: 02/04/2010

Medical Identifiers

Medical identifiers for Dr Charles Jaffe such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1114259827	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207K00000X	Allergy & Immunology	C37310 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Charles Jaffe is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Charles Jaffe, MD, PHD 1619 Forest Way, Del Mar, CA 92014-2430 Ph: (858) 720-8200	Dr Charles Jaffe, MD, PHD 1619 Forest Way, Del Mar, CA 92014-2430 Ph: (858) 720-8200

News Archive

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

Viking Systems raises $934,897 through sale of common stock

Viking Systems Inc. announced today that it has increased its cash and liquidity position through the issuance of common stock. The Company raised $934,897 by selling an aggregate of 4,398,050 shares of its common stock through its previously announced financing facility with Dutchess Opportunity Fund, II, LP.

New manual by psychologist explains basics of hypnotherapy

Hypnotic Relaxation Therapy: Principles and Applications (Springer Publishing) is a new training manual by Gary Elkins, Ph.D., director of the Mind-Body Medicine Research Laboratory at Baylor University.

SARS-CoV-2 unique deletion variants found in clinical specimens

While participating in the SPHERES Consortium project, US researchers sequenced 2,726 clinical patient specimens gathered in March 2020 and identified eight unique ORF7a deletion variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their results are currently available on the bioRxiv* preprint server.

New scientific report finds many areas for improvement in online dating industry

The report card is in, and the online dating industry won't be putting this one on the fridge. A new scientific report concludes that although online dating offers users some very real benefits, it falls far short of its potential.

Dr Charles Jaffe, MD, PHD - Allergy & Immunology in Del Mar, CA